- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04745988
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Akihito Kawazoe, MD
- Phone Number: +81-4-7133-1111
- Email: LenvaPem_core@east.ncc.go.jp
Study Locations
-
-
Chiba
-
Kashiwa, Chiba, Japan
- Recruiting
- National Cancer Center Hospital East
-
Contact:
- Akihito Kawazoe, MD
- Phone Number: +81-4-7133-1111
- Email: LenvaPem_core@east.ncc.go.jp
-
Principal Investigator:
- Akihito Kawazoe, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have gastric and gastroesophageal junction adenocarcinoma
- Untreated and cT2-4 and/or cN+ without evidence of metastatic disease
- Patients at least 20 years of age on the day of providing consent.
- Patients with a performance status of 0 or 1 on the Eastern Cooperative Oncology Group.
Patients with adequate organ function at the time of enrollment as defined below:
- Neutrophil count ≥1500mm3
- Platelet count ≥10 × 100,000/mm3
- Hemoglobin (Hb) ≥ 9.0 g/dL,
- Total bilirubin ≤1.5 mg/dL
- AST (GOT) and ALT (GPT) ≤ 100 IU/L
- Creatinine ≤1.5 mg/dL
- Urinary protein : It satisfies one of the following (if any of the inspection criteria are satisfied, other examination may not be carried out) (i) urinary protein (test paper method) is 2+ or less (ii) Urine Protein Creatinine (UPC) ratio <3.5 (iii) 24-hour urine protein was measured, urinary protein ≦ 3500 mg
- International normalized ratio (INR) ≤ 1.5
- Patients who not received a blood transfusion within 14 days of registration.
- Patients have recovered adverse events associated with radiation and surgical operation as pretreatment to Grade 1 or less or baseline or less with CTCAE v5.0 excluding stable symptoms. However, adverse events with stable symptoms even with Grade 2 or higher excluded.
- Female of childbearing potential who are negative in a pregnancy test within 14 days before enrollment. Both male and female patients should agree to use an adequate method of contraception (total abstinence or use of a male condom plus partner use of contraceptive method [an intrauterine device or hormone releasing system, a contraceptive implant and an oral contraceptive]) starting with the first dose of study therapy through 120 days after the last dose of study therapy. Duration will be determined when the subject is assigned to treatment.
- Patients capable of taking oral medication.
- Patients who provided written informed consent to be subjects in this study.
Exclusion Criteria:
- Patients who have undergone surgical treatment and radiotherapy within 2 weeks before enrollment.
- Patients with hypertension that is difficult to control (systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥90 mmHg) despite treatment with several hypotensive agents.
- Patients with acute coronary syndrome (including myocardial infarction and unstable angina), and with a history of coronary angioplasty or stent placement performed within 6 months before enrollment.
- Patients with a history of New York Heart Association congestive heart failure of grade II or above, unstable angina, myocardial infarction.
- Patients have an addigional active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 24 months.
- Patients have severe (hospitalization required) complications (intenstinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, mental disease, cerebrovascular disease etc).
- Patients with a history of a gastrointestinal perforation and /or gastrointestinal fistula within 6 months before enrollment.
- Is infected with active hepatitis B (defined as HBs antigen positive) or hepatitis C.
- Patients with a history of human immunodeficiency virus (HIV).
- Patients with a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- Patients who are administered live vaccines <30 days before the initiation of treatment with the investigational drug.
- Patients with concurrent autoimmune disease, or a history of chronic or recurrent autoimmune disease.
- Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to alleviate swelling associated with radiotherapy) or immunosuppressants, or who have received such a therapy <14 days before enrollment.
- Patients have serious non-healing wound, ulcer, or bone fracture.
- Females who are pregnant or breastfeeding.
- Patients have no intention to comply with the protocol or cannot comply.
- Patients were judged unsuitable as subject of this study by investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lenvatinib Plus Pembrolizumab
One cycle is 21 days, with Lenvatinib plus Pembrolizumab repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
|
Lenvatinib will be administered at a dose of 20mg as oral dose, once a day.
Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
|
Experimental: Lenvatinib, Pembrolizumab Plus FLOT
One cycle is 21 days, with Lenvatinib, Pembrolizumab plus FLOT repeated 3 cycles before surgery and 3 cycles after surgery, followed by 11 cycles of pembrolizumab monotherapy as the adjuvant treatment.
|
Pembrolizumab will be administered at a dose of 200mg as a 30-minutes IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
Lenvatinib will be administered at a dose of 8mg as oral dose, once a day.
Docetaxel will be administered at a dose of 50mg/m^2 as a IV infusion, Q2W.
Oxaliplatin will be administered at a dose of 85mg/m^2 as a IV infusion, Q2W.
Levofolinate will be administered at a dose of 200mg/m^2 as a IV infusion, Q2W.
Levofolinate will be administered at a dose of 2600mg/m^2 as a IV infusion, Q2W.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major pathological response (MPR) rate
Time Frame: 6 months
|
The MPR rate will be defined as the proportion of patients whose percentage of residual tumor in the stomach and lymph node decreased to < 10%, as determined by a pathologist.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological complete response (pCR) rate
Time Frame: 6 months
|
The pCR rate will be defined as the proportion of patients whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist.
|
6 months
|
Tumor response in the gastric primary lesion
Time Frame: 6 months
|
The number of patients achieving endoscopic CR, PR, SD, or PD will be separately tabulated.
|
6 months
|
Radical resection rate
Time Frame: 6 months
|
The radical resection rate will be defined as the proportion of patients who underwent a radical resection (R0 resection).
|
6 months
|
Treatment completion rate until surgery
Time Frame: 6 months
|
The treatment completion rate will be defined as the proportion of patients who started the protocol treatment, completed a three-cycle treatment with the study drug, and then underwent a radical resection (R0 resection).
|
6 months
|
Treatment completion rate until adjuvant treatment
Time Frame: 1 year 8 months
|
The treatment completion rate will be defined as the proportion of patients who started the protocol treatment, completed a three-cycle treatment with the study drug, and then underwent a radical resection (R0 resection) and adjuvant treatment was performed up to 14 cycles.
|
1 year 8 months
|
Event free survival (EFS)
Time Frame: 3 years
|
The registration date is the starting date, and is defined as the period until the event that occurs any of the following.
Secondary primary malignancies are not an EFS event. Patients for whom no EFS event has been recorded will be censored on the final image evaluation date. |
3 years
|
Overall survival (OS)
Time Frame: 3 years
|
The period will be from the day of enrollment, as the starting date of the computation, to the day of death of any cause. Surviving patients should be censored on the last day of PFS confirmed (Confirmation of survival by telephone inquiry will be acceptable. However, the fact of confirming survival should be documented in medical records.). Patients who are lost to follow up should be censored on the last day when their survival is confirmed before being lost to follow up. |
3 years
|
The incidence of adverse events
Time Frame: Up to 30 days after the last dose
|
For adverse events due to protocol treatment, determine the frequency of worst grades in all courses according to CTCAE v5.0, the incidence of adverse events of Grade 3 or higher, and the incidence of adverse events of Grade 4 or higher.
|
Up to 30 days after the last dose
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Protective Agents
- Antineoplastic Agents, Immunological
- Micronutrients
- Protein Kinase Inhibitors
- Vitamins
- Antidotes
- Vitamin B Complex
- Docetaxel
- Fluorouracil
- Oxaliplatin
- Pembrolizumab
- Leucovorin
- Levoleucovorin
- Lenvatinib
Other Study ID Numbers
- EPOC2001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Lenvatinib 20mg
-
Onconic Therapeutics Inc.CompletedHealthyKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterCompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Anji PharmaCovanceCompletedFunctional ConstipationChina, United States
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted
-
Medicines for Malaria VentureQ-Pharm Pty LimitedTerminatedMalaria, FalciparumAustralia
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Mitsubishi Tanabe Pharma CorporationCompletedType 2 Diabetes MellitusChina
-
PfizerCompletedHealthy Volunteers | Hepatic ImpairmentUnited States
-
Impact Therapeutics, Inc.Not yet recruiting
-
Onconic Therapeutics Inc.Not yet recruiting